文献速递泌尿生殖腹部MR

有无胰高血糖素的前列腺T2加权自旋回波MRI:配对扫描质量评估

Prostate T2-weighted spin-echo MRI with and without glucagon: a paired scan quality assessment.
PubMed 文献 · Abdom Radiol (NY) · 2025-10-13

本研究在本机构对33例临床前列腺MRI检查前接受1 mg皮下胰高血糖素的患者,加做一次无胰高血糖素的研究扫描,比较两种T2加权自旋回波序列的图像质量。总体无显著差异,但按扫描时间比分层后,低时间比组中胰高血糖素扫描的诊断质量、PI-QUALv2评分、运动伪影评分及阅片者偏好均显著改善。结论认为当扫描时间不超过无胰高血糖素序列的1.25倍时,皮下胰高血糖素可改善图像质量,获益随扫描时间延长而减弱。

要点

  • 本机构常规在临床前列腺MRI扫描前给予1 mg皮下胰高血糖素。
  • 总体33例中,有无胰高血糖素的T2-WI图像质量无显著差异。
  • 扫描时间比≤1.25倍时,胰高血糖素扫描的诊断质量、PI-QUALv2、运动伪影及阅片者偏好均显著改善。

核心结论

  • 皮下胰高血糖素可改善前列腺T2-WI MRI的图像质量,但前提是扫描时间不超过无胰高血糖素T2-WI序列的1.25倍,获益随扫描时间延长而减弱。

研究设计与样本

  • 在本机构开展的前后配对扫描质量评估,2024年2月15日至2025年2月11日共招募33例临床前列腺MRI检查前接受1 mg皮下胰高血糖素的患者,加做一次无胰高血糖素的研究扫描,所有检查均在3T设备上完成,比较轴位T2加权自旋回波序列。

关键影像表现/征象

  • T2-WI序列由三名经验丰富的放射科医生评估,评估内容包括诊断质量(0-3分)、PI-QUALv2(0-3分总和)、运动伪影(显著、可见、无)及阅片者偏好(五点相对量表)。
  • 因预设覆盖范围不同,每例受试者两次T2-WI序列的扫描时间通常不同,结果按胰高血糖素扫描与无胰高血糖素扫描的采集时间比(Trel)进行分层。

诊断标准与关键数值

  • 诊断质量采用0-3分评分,PI-QUALv2采用0-3分总和评分,运动伪影分为显著、可见、无三级,阅片者偏好采用五点相对量表。
  • 全部33例中,胰高血糖素扫描与无胰高血糖素扫描之间各评分均无显著差异。
  • 低Trel组(N=16)中,胰高血糖素扫描的诊断质量显著改善(p=0.048),PI-QUALv2总分显著改善(p=0.049),运动评分显著改善(p=0.047),阅片者偏好显著改善(p=0.042)。
  • 高Trel组(N=17)中,胰高血糖素偏好与Trel呈负相关(p=0.026),提示扫描时间越长,胰高血糖素的获益越不明显。

临床应用与阅片要点

  • 本研究中心的做法是:患者在接受临床前列腺MRI检查前给予1 mg皮下胰高血糖素。
  • 作者认为,当扫描时间控制在无胰高血糖素T2-WI序列的1.25倍以内时,皮下胰高血糖素可改善前列腺T2-WI的图像质量。
  • 作者指出,胰高血糖素的获益似乎随扫描时间延长而减弱。

局限性

  • 原文指出,由于预设覆盖范围不同,每例受试者两次T2-WI序列的扫描时间通常不同,因此结果需按采集时间比(Trel)分层分析。
  • 原文结论中提出,胰高血糖素的获益似乎随扫描时间延长而减弱,该结论基于观察性配对数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To evaluate the effectiveness of subcutaneous glucagon in reducing motion artifact during prostate MRI through intraindividual comparison.

METHODS: At our institution patients undergoing a clinical prostate MRI exam receive 1 mg of subcutaneous glucagon before scanning. From February 15, 2024 to February 11, 2025 33 such patients were recruited to undergo an additional, research exam without glucagon. All exams were acquired at 3T. An axial T2-weighted spin-echo series (T2-WI) was acquired within both exams. Evaluation of the T2-WI series was done by three experienced radiologists using the criteria of diagnostic quality (0-3 scale), PI-QUALv2 (0-3 sum), motion artifact (significant, visible, none), and reviewer preference (five-point relative scale). Due to differences in prescribed coverage, the scan times for the two T2-WI sequences were in general different for each subject. Results were stratified using the acquisition time ratio (Trel) between the glucagon vs. non-glucagon scans. Wilcoxon tests assessed score differences.

RESULTS: Across all 33 subjects, no significant differences were found between glucagon and non-glucagon scans. However, the observed negative correlation between glucagon preference and Trel (p = 0.026) led to stratification into low-Trel (N = 16) and high-Trel (N = 17) groups. In the low-Trel group the glucagon scans provided significantly improved diagnostic quality (p = 0.048), PI-QUALv2 sum (p = 0.049), motion scores (p = 0.047), and reader preference (p = 0.042).

CONCLUSION: Subcutaneous glucagon provides improved image quality in prostate T2-WI MRI when scan duration remains within 1.25× of that of a non-glucagon T2-WI series. The benefit appears to decrease with longer scan times.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Hassanzadeh S, Borisch EA, Froemming AT, et al. Prostate T2-weighted spin-echo MRI with and without glucagon: a paired scan quality assessment. Abdom Radiol (NY). 2025. PMID: 41081882. doi:10.1007/s00261-025-05215-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。